the akampioneer

Food for Thought: How to (Not?) Create a Buzz With Your Corporate Press Release

akampion — Wed, 30 May 2012 09:07:17 +0000

This week, NYC-based Immune Response BioPharma, Inc. announced that the company has terminated partnering discussions on its multiple sclerosis vaccine NeuroVax with GlaxoSmithKline. The news per se may not trigger a lot of interest – but the company has managed to create a significant buzz around its announcement, with CEO David Buswell stating that (quote [...]

Company News: InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member

akampion — Tue, 29 May 2012 08:05:04 +0000

- Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network - InDex Pharmaceuticals today announced that Stig Løkke Pedersen has been appointed as a new member of the Board of Directors. Mr. Pedersen brings to InDex Pharmaceuticals over 25 years of longstanding life sciences industry experience in commercial operations and leadership. Mr. [...]

Company News: Curetis AG Achieves CE-Marking for Unyvero™ Solution and Initiates Commercialization

akampion — Mon, 14 May 2012 08:00:40 +0000

- Successful completion of performance evaluation study; CE Mark for Unyvero™ instrument system and pneumonia application - Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced that the company has achieved the CE marking for its Unyvero™ suite of instruments and the [...]

Innovation Radar: Probiodrug’s Nature Paper Receives Broad Coverage

akampion — Fri, 04 May 2012 08:09:12 +0000

This week’s Nature publication by researchers of Probiodrug AG and the University of Virginia has received broad coverage in the international media. In Germany and Austria, it made major news in TV (ARD, MDR, ORF) and radio stations (dlf, MDR, dradio), while in the US Rudy Tanzi, neurogeneticist of Harvard Medical School and an advisor on the [...]

Company News: Jean-Paul Prieels joins VAXIMM’s Board of Directors

akampion — Thu, 03 May 2012 08:11:52 +0000

VAXIMM AG, a Swiss-German biotech spin-off from Merck KGaA focusing on cancer vaccines, announced today the appointment of Jean-Paul Prieels as a new member of its Board of Directors. Dr. Prieels is a renowned industry expert in the vaccine field. He held various executive positions at GlaxoSmithKline, where he headed the vaccine research and development [...]